Pharmafile Logo
Pharmafocus logo
Advanced Search

GSK pledges £45m to Fleming Initiative to fight AMR

May 16, 2024
Research and Development AMR, Fleming Initiative, GSK, Microbiology, funding

GSK has announced that it has pledged £45m to the Fleming Initiative, becoming the first founding partner of the innovative …

News

NeuroSense partners with PhaseV on upcoming phase 3 ALS trial

May 16, 2024
Research and Development NeuroSense, Neurology, als, clinical trials

NeuroSense has announced that it has partnered with PhaseV for its upcoming phase 3 trial of PrimeC as a treatment …

News

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

May 15, 2024
Research and Development AstraZeneca, BenevolentAI, Cardiology, collaboration, heart failure

BenevolentAI has announced that AstraZeneca has added a novel heart failure target to its discovery portfolio following the two companies’ …

News

FDA approves Roche’s HPV self-collection screening option

May 15, 2024
Medical Communications FDA, HPV, Oncology, Roche, cervical cancer

Roche has announced that the US Food and Drug Administration (FDA) has approved its human papillomavirus (HPV) self-collection solution. This …

News

NHS accepts Pfizer’s tafamidis for ATTR-CM treatment

May 14, 2024
Medical Communications ATTR-CM, Cardiology, NHS, Pfizer, tafamidis

NHS England has announced that it has accepted Pfizer’s drug, tafamidis, for the treatment of transthyretin amyloidosis cardiomyopathy (ATTR-CM).

News

Fulcrum Therapeutics and Sanofi enter collaboration for facioscapulohumeral muscular dystrophy treatment

May 14, 2024
Research and Development Musculo-skeletal disorder, Sanofi, collaboration, fulcrum therapeutics, muscular dystrophy

Fulcrum Therapeutics has announced that it has entered into a collaboration and license agreement with Sanofi for the development and …

News

PharmaTimes Medical & Scientific Excellence Awards and Nursing Industry Excellence Awards are open for entry

May 13, 2024
Business Services MSEA, NIEA, PharmaTimes, awards

Both awards are open for entry until 17 May 2024 and the live awards ceremony will take place on 11 …

News
Press release

Sanofi adds €1bn funding for biomanufacturing projects in France

May 13, 2024
Business Services Biomanufacturing, Pharmacy, Sanofi, funding, investment

Sanofi has announced that it has made a new investment of at least €1bn for the creation of new bioproduction …

News

Moderna shares update on RSV vaccine

May 13, 2024
Medical Communications FDA, Immunology, Moderna, Vaccine

Moderna has announced that the US Food and Drug Administration (FDA) has shared that it will not complete its review …

News
genes

Shionogi and Maze Therapeutics announce worldwide exclusive licensing agreement for novel Pompe disease candidate

May 10, 2024
Sales and Marketing Pompe disease, Rare Diseases, Shionogi, licensing agreement, maze therapeutics

Japanese pharmaceutical company Shionogi and US-based Maze Therapeutics have finalised an exclusive worldwide license agreement for MZE001, a novel therapeutic …

News
Vaccine image

Sanofi and Novavex sign exclusive $1.2bn licensing agreement to co-commercialise COVID-19 vaccine and develop flu-COVID-19 vaccines

May 10, 2024
Sales and Marketing COVID-19, COVID-19 vaccine, Immunology, Novatex, Sanofi, flu-COVID-19 vaccine, licensing agreement

French pharma and healthcare company Sanofi and US biotech Novavex, have entered into a co-exclusive licensing agreement for a number …

News
az_vaccine

AstraZeneca withdraws COVID-19 vaccine Vaxzevria

May 9, 2024
Sales and Marketing AstraZeneca, COVID-19, Immunology, thrombosis with thrombocytopenia syndrome

UK-based pharmaceutical company AstraZeneca has announced that is it voluntarily withdrawing its COVID-19 vaccine Vaxzevria due to a drop in …

News
dementia image

Nxera Pharma partner Neurocrine Biosciences enters phase 1 NBI-1117567 study

May 9, 2024
Research and Development Alzheimer's disease, Neurocrine Biosciences, Neurology, Nxera Pharma, Parkinson's disease, clinical trials, dementia, schizophrenia

Nxera Pharma’s neuroscience-focused biopharmaceutical partner  Neurocrine Biosciences has announced it has successfully started its phase 1, first-in-human trial of investigational …

News

Mirum Pharmaceuticals publishes phase 3 MARCH maralixibat data in The Lancet

May 8, 2024
Research and Development Hepatology, Mirum Pharmaceuticals, PFIC, The Lancet, clinical trials

Biopharma company Mirum Pharmaceuticals has announced data from its phase 3 MARCH-PFIC study which evaluated maralixibat in patients with progressive …

News
biology-think-networking-physiology-brain-anatomy-2676370

Circular Genomics reveals study results into predicting patient response to SSRI antidepressant treatment

May 8, 2024
Research and Development Circular Genomics, Psychiatry, SSRI, antidepressant treatment, blood assays

US RNA biomarker company Circular Genomics has announced study results highlighting the company’s first blood assay to predict a patient’s …

News
lungs

Gossamer Bio and Chiesi Group enter into international collaboration to commercialise Seralutinib

May 7, 2024
Research and Development Chiesi, Chronic Diseases, Gossamer Bio, PAH, PH-ILD, collaboration

US-based clinical stage biopharma company Gossamer Bio and Italian research-focused biopharma group Chiesi Farmaceutici have entered into an international agreement …

News
trials

Broken String Biosciences and the Francis Crick Institute collaborate on ALS research

May 7, 2024
Research and Development Broken String Biosciences, Francis Crick Institute, Neurology, amyotrophic lateral sclerosis, genomics

Genomics company Broken String Biosciences and biomedical discovery institute Francis Crick have announced a research collaboration, focusing on amyotrophic lateral …

News

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024
Research and Development AbbVie, Pharmacy, R&D, facility

AbbVie has announced that it is investing approximately €150m in its second largest research and development (R&D) facility worldwide. The …

News

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024
Medical Communications AstraZeneca, Calquence, Oncology, clinical trial, lymphoma

AstraZeneca has announced positive high-level results from an interim analysis of the ECHO phase 3 trial, which assessed Calquence (acalabrutinib) …

News

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024
Research and Development Gastric, MSD, Merck, Oncology, keytruda

Merck, known as MSD outside of the US and Canada, has announced data from the phase 3 KEYNOTE-811 trial which …

News

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024
Medical Communications COPD, Cardiology, clinical trial, verona pharma

Verona Pharma has announced that it will share eight posters at the American Thoracic Society International Conference (ATS) 2024, including …

News

Latest content

GSK pledges £45m to Fleming Initiative to fight AMR

May 16, 2024

NeuroSense partners with PhaseV on upcoming phase 3 ALS trial

May 16, 2024

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

May 15, 2024

FDA approves Roche’s HPV self-collection screening option

May 15, 2024

NHS accepts Pfizer’s tafamidis for ATTR-CM treatment

May 14, 2024